Immune activation in irritable bowel syndrome: Can neuroimmune interactions explain symptoms

American Journal of Gastroenterology

Volumn 108, Issue 7, 2013, Pages 1066-1074

  Hughes, Patrick A ^a,b,c   Zola, Heddy ^a,c   Penttila, Irmeli A ^a,c   Blackshaw, L Ashley ^a,b,c,d,e   Andrews, Jane M ^a,b   Krumbiegel, Doreen ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c CHILD HEALTH RESEARCH INSTITUTE   (Australia)

^d Centre for Adult and Paediatric Gastroenterology   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA DEFENSIN 2; BETA ENDORPHIN; CD68 ANTIGEN; CXCL9 CHEMOKINE; ENKEPHALIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PROTEINASE ACTIVATED RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BACTERIAL STRAIN; CELL DIFFERENTIATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CORRELATION ANALYSIS; DENDRITIC CELL; EOSINOPHIL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTESTINE FLORA; IRRITABLE COLON; MACROPHAGE; MAST CELL; MAST CELL DEGRANULATION; META ANALYSIS (TOPIC); NEUROIMMUNOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; COLON; GASTROINTESTINAL TRACT; HUMANS; IMMUNITY, INNATE; IRRITABLE BOWEL SYNDROME; MAST CELLS; METAGENOME; NEUROIMMUNOMODULATION; T-LYMPHOCYTES;

EID: 84880296547     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.120     Document Type: Article

References (120)

1. Longstreth GF , Th ompson WG , Chey WD et al. Functional bowel disorders. Gastroenterology 2006 ; 130 : 1480-91.
2. Ohman L , Simren M. Pathogenesis of IBS: role of infl ammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010 ; 7 : 163-73.
3. Spiller R , Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009 ; 136 : 1979-88.
4. Hughes PA , Brierley SM , Martin CM et al. Post-infl ammatory colonic aff erent sensitisation: diff erent subtypes, diff erent pathways and diff erent time courses. Gut 2009 ; 58 : 1333-41.
5. Hughes PA , Brierley SM , Blackshaw LA. Post-infl ammatory modifi cation of colonic aff erent mechanosensitivity. Clin Exp Pharmacol Physiol 2009 ; 36 : 1034-40.
6. Kassinen A , Krogius-Kurikka L , Makivuokko H et al The fecal microbiota of irritable bowel syndrome patients diff ers signifi cantly from that of healthy subjects. Gastroenterology 2007 ; 133 : 24-33.
7. Matto J , Maunuksela L , Kajander K et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005 ; 43 : 213-22.
8. Codling C , O ' Mahony L , Shanahan F et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010 ; 55 : 392-7.
9. Rajilic-Stojanovic M , Biagi E , Heilig HG et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011 ; 141 : 1792-801.
10. Eckburg PB , Bik EM , Bernstein CN et al. Diversity o. The human intestinal microbial fl ora. Science 2005 ; 308 : 1635-8.
11. Gallego D , Clave P , Donovan J et al. The gaseous mediator, hydrogen sulphide, inhibits in vitro motor patterns i. The human, rat and mouse colon and jejunum. Neurogastroenterol Motil 2008 ; 20 : 1306-16.
12. Xu GY , Winston JH , Shenoy M et al. The endogenous hydrogen sulfi de producing enzyme cystathionine-beta synthase contributes to visceral hypersensitivity in a rat model of irritable bowel syndrome. Mol Pain 2009 ; 5 : 44.
13. Tana C , Umesaki Y , Imaoka A et al. Altered profi les of intestinal microbiota and organic acids may bethe origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010 ; 22 : 512-9.
14. Liu CY , Jiang W , Muller MH et al. Sensitization of mesenteric aff erents to chemical and mechanical stimuli following systemic bacterial lipopolysaccharide. Neurogastroenterol Motil 2005 ; 17 : 89-101.
15. Ochoa-Cortes F , Ramos-Lomas T , Miranda-Morales M et al. Bacterial cell products signal to mouse colonic nociceptive dorsal root ganglia neurons. Am J Physiol Gastrointest Liver Physiol 2010 ; 299 : G723 - 32.
16. Roka R , Rosztoczy A , Leveque M et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007 ; 5 : 550-5.
17. Gecse K , Roka R , Ferrier L et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008 ; 57 : 591-9.
18. Annahazi A , Gecse K , Dabek M et al. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite eff ect on visceral sensitivity in mice. Pain 2009 ; 144 : 209-17.
19. Schoepfer AM , Schaff er T , Seibold-Schmid B et al. Antibodies to fl agellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008 ; 20 : 1110-8.
20. Dlugosz A , Tornblom H , Mohammadian G et al. Chlamydia trachomatis antigens in enteroendocrine cells and macrophages o. The small bowel in patients with severe irritable bowel syndrome. BMC Gastroenterol 2010 ; 10 : 19.
21. Halpern GM , Prindivillet , Blankenburg M et al. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996 ; 91 : 1579-85.
22. McKernan DP , Fitzgerald P , Dinan TG et al. Th e probiotic Bifi dobacterium infantis 35624 displays visceral antinociceptive eff ects i. The rat. Neurogastroenterol Motil 2010 ; 22 : 1029-35.
23. O ' Mahony L , McCarthy J , Kelly P et al. Lactobacillus and bifi dobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profi les. Gastroenterology 2005 ; 128 : 541-51.
24. Kamiya T , Wang L , Forsythe P et al. Inhibitory eff ects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006 ; 55 : 191-6.
25. Rousseaux C , Th uru X , Gelot A et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007 ; 13 : 35-7.
26. Pimentel M , Lembo A , Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011 ; 364 : 22-32.
27. Menees SB , Maneerattannaporn M , Kim HM et al. The effi cacy and safety of rifaximin fo. The irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012 ; 107 : 28-35.
28. Quigley EM. Probiotics in functional gastrointestinal disorders: what arethe facts? Curr Opin Pharmacol 2008 ; 8 : 704-8.
29. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. Jama 2004 ; 292 : 852-8.
30. Ford AC , Spiegel BM , Talley NJ et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009 ; 7 : 1279-86.
31. Langhorst J , Junge A , Rueff er A et al. Elevated human beta-defensin-2 levels indicate an activation o. The innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009 ; 104 : 404-10.
32. Aerssens J , Camilleri M , Talloen W et al. Alterations in mucosal immunity identifi ed i. The colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008 ; 6 : 194-205.
33. Dunlop SP , Hebden J , Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006 ; 101 : 1288-94.
34. Zhou Q , Zhang B , Verne GN. Intestinal membrane permeability and hypersensitivity i. The irritable bowel syndrome. Pain 2009 ; 146 : 41-6.
35. Pichet , Barbara G , Aubert P et al. Impaired intestinal barrier integrity i. The colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009 ; 58 : 196-201.
36. Zhou Q , Souba WW , Croce CM et al. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010 ; 59 : 775-84.
37. Vivinus-Nebot M , Dainese R , Anty R et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 2012 ; 107 : 75-81.
38. Zeng J , Li YQ , Zuo XL et al. Clinical trial: eff ect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoeapredominant irritable bowel syndrome. Aliment Pharmacol Th er 2008 ; 28 : 994-1002.
39. Gecse K , Roka R , Sera T et al. Leaky gut in patients with diarrheapredominant irritable bowel syndrome and inactive ulcerative colitis. Digestion 2012 ; 85 : 40-6.
40. Villani AC , Lemire M , Th abane M et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010 ; 138 : 1502-13.
41. Martinez C , Vicario M , Ramos L et al. Th e jejunum of diarrheapredominant irritable bowel syndrome shows molecular alterations in thetight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 2012 ; 107 : 736-46.
42. Martinez C , Lobo B , Pigrau M et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities i. The jejunal epithelial barrier. Gut advance online publication, 25 May 2012; doi:10.1136/gutjnl-2012-302093.
43. Bertiaux-Vandaele N , Youmba SB , Belmonte L et al. Th e expression an. The cellular distribution of thetight junction proteins are altered in irritable bowel syndrome patients with diff erences according t. The disease subtype. Am J Gastroenterol 2011 ; 106 : 2165-73.
44. Coeffi er M , Gloro R , Boukhettala N et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010 ; 105 : 1181-8.
45. Dinan TG , Quigley EM , Ahmed SM et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006 ; 130 : 304-11.
46. McKernan DP , Gaszner G , Quigley EM et al. Altered peripheral toll-like receptor responses i. The irritable bowel syndrome. Aliment Pharmacol Th er 2011 ; 33 : 1045-52.
47. Dinan TG , Clarke G , Quigley EM et al. Enhanced cholinergic-mediated increase i. The pro-infl ammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 2008 ; 103 : 2570-6.
48. O ' Sullivan M , Clayton N , Breslin NP et al. Increased mast cells i. The irritable bowel syndrome. Neurogastroenterol Motil 2000 ; 12 : 449-57.
49. Chadwick VS , Chen W , Shu D et al. Activation o. The mucosal immune system in irritable bowel syndrome. Gastroenterology 2002 ; 122 : 1778-83.
50. Pichet , Saint-Paul MC , Dainese R et al. Mast cells and cellularity o. The colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008 ; 57 : 468-73.
51. Dunlop SP , Jenkins D , Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003 ; 98 : 1578-83.
52. Cremon C , Carini G , Wang B et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011 ; 106 : 1290-8.
53. Cremon C , Gargano L , Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009 ; 104 : 392-400.
54. Buhner S , Li Q , Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009 ; 137 : 1425-34.
55. Barbara G , Stanghellini V , De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004 ; 126 : 693-702.
56. Barbara G , Wang B , Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007 ; 132 : 26-37.
57. Wang LH , Fang XC , Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004 ; 53 : 1096-101.
58. Weston AP , Biddle WL , Bhatia PS et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993 ; 38 : 1590-5.
59. Foley S , Garsed K , Singh G et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 2011 ; 140 : 1434-43.
60. Guilarte M , Santos J , detorres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia i. The jejunum. Gut 2007 ; 56 : 203-9.
61. Park JH , Rhee PL , Kim HS.et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006 ; 21 : 71-8.
62. Braak B , Klooker TK , Wouters MM et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol 2012 ; 107 : 715-26.
63. Dunlop SP , Jenkins D , Neal KR et al. Relative importance of enterochromaffi n cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003 ; 125 : 1651-9.
64. Spiller RC , Jenkins D , Th ornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000 ; 47 : 804-11.
65. Tornblom H , Lindberg G , Nyberg B et al. Full-thickness biopsy o. The jejunum reveals infl ammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002 ; 123 : 1972 - 9.
66. Cenac N , Andrews CN , Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007 ; 117 : 636-47.
67. Klooker TK , Braak B , Koopman KE et al. Th e mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010 ; 59 : 1213-21.
68. Kerckhoff s AP , Ter Linde JJ , Akkermans LM et al. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 2008 ; 20 : 900-7.
69. Forshammar J , Isaksson S , Strid H et al. A pilot study of colonic B cell pattern in irritable bowel syndrome. Scand J Gastroenterol 2008 ; 43 : 1461-6.
70. Zuo XL , Li YQ , Li WJ et al. -specifi c serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy 2007 ; 37 : 823-30.
71. Zar S , Benson MJ , Kumar D. Food-specifi c serum IgG4 and Igetiters to common food antigens in irritable bowel syndrome. Am J Gastroenterol 2005 ; 100 : 1550-7.
72. Galli SJ , Grimbaldeston M , Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008 ; 8 : 478-86.
73. Macsharry J , O ' Mahony L , Fanning A.et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008 ; 43 : 1467-76.
74. Brint EK , MacSharry J , Fanning A et al. Diff erential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011 ; 106 : 329-36.
75. Lavelle EC , Murphy C , O ' Neill LA et al. Th e role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol 2010 ; 3 : 17-28.
76. Murray PJ , Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011 ; 11 : 723-37.
77. Kristjansson G , Venge P , Wanders A et al. Clinical and subclinical intestinal infl ammation assessed b. The mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in infl ammatory bowel diseases and irritable bowel syndrome. Gut 2004 ; 53 : 1806-12.
78. Kindt S , Van Oudenhove L , Broekaert D et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009 ; 21 : 389-98.
79. Walker MM , Talley NJ , Prabhakar M et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers i. The irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Th er 2009 ; 29 : 765-73.
80. Walker MM , Salehian SS , Murray CE et al. Implications of eosinophilia i. The normal duodenal biopsy - an association with allergy and functional dyspepsia. Aliment Pharmacol Th er 2010 ; 31 : 1229-36.
81. Akbar A , Yiangou Y , Facer P. et al. Increased capsaicin receptor TRPV1- expressing sensory fi bres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008 ; 57 : 923-9.
82. Ohman L , Isaksson S , Lindmark AC et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009 ; 104 : 1205-12.
83. Ohman L , Isaksson S , Lundgren A et al. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005 ; 3 : 980-6.
84. Elsenbruch S , Holtmann G , Oezcan D et al. Arethere alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am J Gastroenterol 2004 ; 99 : 703-10.
85. Liebregts T , Adam B , Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007 ; 132 : 913-20.
86. Schmulson M , Pulido-London D , Rodriguez O et al. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 2012 ; 107 : 747-53.
87. Hughes PA , Harrington AM , Castro J et al. Sensory neuro-immune interactions diff er between irritable bowel syndrome subtypes. Gut advance online publication, 27 July 2012 ; doi:10.1136/gutjnl-2011-301856.
88. Liebregts T , Adam B , Bredack C et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011 ; 106 : 1089-98.
89. Scully P , McKernan DP , Keohane J et al. Plasma cytokine profi les in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010 ; 105 : 2235-43.
90. Swan C , Duroudier NP , Campbell E et al. Identifying and testing candidate genetic polymorphisms i. The irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha. Gut advance online publication, 8 June 2012 ; doi:10.1136/gutjnl-2011-301213.
91. Chang L , Adeyemo M , Karagiannides I et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012 ; 107 : 262-72.
92. van der Veek PP , van den Berg M , de Kroon YE et al. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005 ; 100 : 2510-6.
93. Gonsalkorale WM , Perrey C , Pravica V et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an infl ammatory component? Gut 2003 ; 52 : 91-3.
94. Barkhordari E , Rezaei N , Ansaripour B et al. Proinfl ammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol 2010 ; 30 : 74-9.
95. Barkhordari E , Rezaei N , Mahmoudi M et al. T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. Infl ammation 2010 ; 33 : 281-6.
96. Bashashati M , Rezaei N , Bashashati H et al. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2012 ; 24 : 1102 - e566.
97. Nakayamada S , Takahashi H , Kanno Y et al. Helper T cell diversity and plasticity. Curr Opin Immunol 2012 ; 24 : 297-302.
98. Holmen N , Isaksson S , Simren M et al. CD4+CD25+ regulatory T cells in irritable bowel syndrome patients. Neurogastroenterol Motil 2007 ; 19 : 119-25.
99. Shen W , Durum SK. Synergy of IL-23 and Th 17 cytokines: new light on infl ammatory bowel disease. Neurochem Res 2010 ; 35 : 940-6.
100. 100. Kim CF , Moalem-Taylor G. Interleukin-17 contributes to neuroinfl ammation and neuropathic pain following peripheral nerve injury in mice. J Pain 2011 ; 12 : 370-83.
101. Eastaff -Leung N , Mabarrack N , Barbour A et al. Foxp3+ regulatory T cells, Th 17 eff ector cells, and cytokine environment in infl ammatory bowel disease. J Clin Immunol 2010 ; 30 : 80-9.
102. Mikocka-Walus AA , Turnbull DA , Andrews JM et al. Th e eff ect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with infl ammatory bowel disease. Aliment Pharmacol Th er 2008 ; 28 : 475-83.
103. Bryant RV , van Langenberg DR , Holtmann GJ et al. Functional gastrointestinal disorders in infl ammatory bowel disease: impact on quality of life and psychological status. J Gastroenterol Hepatol 2011 ; 26 : 916-23.
104. Ohman L , Lindmark AC , Isaksson S et al. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2009 ; 21 : 644-50.
105. Tornblom H , Lang B , Clover L et al. Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scand J Gastroenterol 2007 ; 42 : 1289-93.
106. Wood JD , Liu S , Drossman DA et al. Anti-enteric neuronal antibodies an. The irritable bowel syndrome. J Neurogastroenterol Motil 2012 ; 18 : 78-85.
107. Jackson MW , Gordon TP , Waterman SA. Disruption of intestinal motility by a calcium channel-stimulating autoantibody in type 1 diabetes. Gastroenterology 2004 ; 126 : 819-28.
108. Park K , Haberberger RV , Gordon TP et al. Antibodies interfering with thetype 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjogren's syndrome. Arthritis Rheum 2011 ; 63 : 1426-34.
109. Ibeakanma C , Vanner S. TNFalpha is a key mediator o. The pronociceptive eff ects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons. Gut 2010 ; 59 : 612-21.
110. Kindt S , Vanden Berghe P , Boesmans W. et al. Prolonged IL-1beta exposure alters neurotransmitter and electrically induced Ca(2+) responses i. The myenteric plexus. Neurogastroenterol Motil 2010 ; 22 : 321 - e85.
111. Xia Y , Hu HZ , Liu S et al. IL-1beta and IL-6 excite neurons and suppress nicotinic and noradrenergic neurotransmission in guinea pig enteric nervous system. J Clin Invest 1999 ; 103 : 1309-16.
112. O ' Malley D , Liston M , Hyland NP et al. Colonic soluble mediators fro. The maternal separation model of irritable bowel syndrome activate submucosal neurons via an interleukin-6-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2011 ; 300 : G241-52.
113. Hughes PA , Brierley SM , Martin CM et al. TRPV1-expressing sensory fi bres and IBS: links with immune function. Gut 2009 ; 58 : 465-6.
114. Labuz D , Schmidt Y , Schreiter A et al. Immune cell-derived opioids protect against neuropathic pain in mice. J Clin Invest 2009 ; 119 : 278-86.
115. Stein C. Th e control of pain in peripheral tissue by opioids. N Engl J Med 1995 ; 332 : 1685-90.
116. Holzer P. Opioid receptors i. The gastrointestinal tract. Regul Pept 2009 ; 155 : 11-7.
117. Verma-Gandhu M , Bercik P , Motomura Y et al. CD4+ T-cell modulation of visceral nociception in mice. Gastroenterology 2006 ; 130 : 1721-8.
118. Elsenbruch S. Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011 ; 25 : 386-94.
119. Peiris M , Bulmer DC , Baker MD et al. Human visceral aff erent recordings: preliminary report. Gut 2011 ; 60 : 204-8.
120. Jiang W , Adam IJ , Kitsanta P et al. ' First-in-man ': characterisin. The mechanosensitivity of human colonic aff erents. Gut 2011 ; 60 : 281-2